PTH Comparison in Post Menopausal Women

Osteoporosis, Post-Menopausal Clinical Trial

Official title:
Comparison of Teriparatide and Calcitonin in the Treatment of Postmenopausal Women With Osteoporosis

Status Completed

Clinical Trial Summary

Compare in postmenopausal women with established osteoporosis the effect of treatment with teriparatide 20 micrograms/day subcutaneous with the effect of salmon calcitonin 100 IU/day subcutaneous on change in lumbar spine BMD.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00543218
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 3
Start date	December 2002
Completion date	June 2004

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00532207` - Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis	Phase 3
Completed	`NCT00018447` - Combination Osteogenic Therapy in Established Osteoporosis	Phase 2
Completed	`NCT00532246` - Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo	Phase 4
Completed	`NCT00543023` - A Study of the Treatment of Postmenopausal Women With Osteoporosis	Phase 3
Completed	`NCT00927186` - Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women	Phase 4
Completed	`NCT00532428` - Long Term Effects of Raloxifene Treatment on Bone Quality	Phase 4
Completed	`NCT00532545` - Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis	Phase 4